Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen Idec Partners With Cardiokine On Vasopressin Antagonist For Hyponatremia

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III trials of the oral drug, which will start this year, are expected to take two years to complete, Biogen says.
Advertisement

Related Content

Biogen Partners With LigoCyte On Anti-CD103 Target
Biogen Partners With LigoCyte On Anti-CD103 Target
Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
Biogen Idec Planning Phase III Studies For Heart Failure Candidate Adentri
Biogen Idec Accelerates Development Of Rheumatoid Arthritis Candidate On Phase IIa Data
Biogen Idec Accelerates Development Of Rheumatoid Arthritis Candidate On Phase IIa Data
Astellas’ Vaprisol Receives Second Indication
Astellas’ Vaprisol Receives Second Indication
Biogen Idec Assumes Aviptadil Development Responsibility From Mondobiotech

Topics

Advertisement
UsernamePublicRestriction

Register

PS066340

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel